Poly[3-(3, 4-dihydroxyphenyl) glyceric acid] from Comfrey exerts anti-cancer efficacy against human prostate cancer via targeting androgen receptor, cell cycle arrest and apoptosis

Carcinogenesis

Volumn 33, Issue 8, 2012, Pages 1572-1580

  Sangeeta, Shrotriya ^a   Gagan, Deep ^a,b   Kumaraguruparan, Ramasamy ^a   Komal, Raina ^a   Vakhtang, Barbakadze ^c   Maia, Merlani ^c   Lali, Gogilashvili ^c   Lela, Amiranashvili ^c   Karen, Mulkijanyan ^c   Kyriakos, Papadopoulos ^d   Chapla, Agarwal ^a,b   Rajesh, Agarwal ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c TBILISI STATE MEDICAL UNIVERSITY   (Georgia)

^d INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDROXY 3 (3,4 DIHYDROXYPHENYL)PROPIONIC ACID; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLANT MEDICINAL PRODUCT; POLY[3 (3,4 DIHYDROXYPHENYL)GLYCERIC ACID]; PROPIONIC ACID DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE REGULATION; COMFREY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; NICK END LABELING; NONHUMAN; PLANT ROOT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; COMFREY; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCERIC ACIDS; HUMANS; MALE; PLANT EXTRACTS; PROSTATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865340823     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs202     Document Type: Article

References (43)

1. Jemal,A. et al. (2010) Cancer statistics, 2010. CA. Cancer J. Clin., 60, 277-300.
2. Chen,C.D. et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat. Med., 10, 33-39.
3. Grossmann, M.E. et al. (2001) Androgen receptor signaling in androgen-refractory prostate cancer. J. Natl. Cancer Inst., 93, 1687-1697.
4. Sharifi,N. et al. (2006) Androgen receptor as a therapeutic target for androgen independent prostate cancer. Am. J. Ther., 13, 166-170.
5. Hanahan,D. et al. (2000) The hallmarks of cancer. Cell, 100, 57-70.
6. Deep,G. et al. (2008) New combination therapies with cell-cycle agents. Curr. Opin. Investig. Drugs, 9, 591-604.
7. Kastan,M.B. et al. (1995) P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev., 14, 3-15.
8. Balk,S.P. et al. (2008) AR, the cell cycle, and prostate cancer. Nucl. Recept. Signal., 6, e001.
9. Liao,X. et al. (2005) Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol. Cancer Ther., 4, 505-515.
10. Abuladze,G.V. et al. (1995) Isolation and pharmacological investigation of polysaccharides from Symphytum asperum. Proc. Georg. Acad. Sci. Biol. Series, 21, 129-132.
11. Barthomeuf,C.M. et al. (2001) Evaluation of the dietetic and therapeutic potential of a high molecular weight hydroxycinnamate-derived polymer from Symphytum asperum Lepech. Regarding its antioxidant, antilipoperoxidant, antiinflammatory, and cytotoxic properties. J. Agric. Food Chem., 49, 3942-3946.
12. Mulkijanyan,K. et al. (2009) Burn healing compositions from Caucasian speceies of Comfrey (Symphytum L.). Bulletin of the Georgian National Academy of Sciences, 3, 114-117.
13. Schäfer,M. et al. (2008) Cancer as an overhealing wound: an old hypothesis revisited. Nat. Rev. Mol. Cell Biol., 9, 628-638.
14. Barbakadze,V. et al. (2005) Poly[3-(3,4-dihydroxyphenyl)glyceric acid], a new biologically active polymer from Symphytum asperum Lepech. and S. caucasicum Bieb. (Boraginaceae). Molecules, 10, 1135-1144.
15. Barbakadze,V. et al. (2008) Effects of Poly[3-(3,4-dihydroxyphenyl) glyceric acid] on the Inflammatory Response of Tumor-Activated Hepatic Sinusoidal Endothelium. Bulletin of the Georgian National Academy of Sciences, 2, 108-112.
16. Barbakadze,V. et al. (2002) Poly[3-(3,4-dihydroxyphenyl)glyceric acid]: a new biologically active polymer from two comfrey species Symphytum asperum and S. caucasicum (Boraginaceae). Russ. J. Bioorg. Chem. 28, 362-330.
17. Barbakadze,V. et al. (2000) Structure of a new anticomplementary dihydroxycinnamate-derived polymer from Symphytum asperum (Boraginaceae). Mendeleev Communications, 10, 148-149.
18. Merlani,M. et al. (2010) Enantioselective synthesis and antioxidant activity of 3-(3,4-dihydroxyphenyl)-glyceric acid-basic monomeric moiety of a biologically active polyether from Symphytum asperum and S. caucasicum. Chirality, 22, 717-725.
19. Kaur,M. et al. (2009) Gallic acid, an active constituent of grape seed extract, exhibits anti-proliferative, pro-apoptotic and anti-tumorigenic effects against prostate carcinoma xenograft growth in nude mice. Pharm. Res., 26, 2133-2140.
20. Kaur,M. et al. (2008) Grape seed extract induces cell cycle arrest and apoptosis in human colon carcinoma cells. Nutr. Cancer, 60 Suppl 1, 2-11.
21. Faith,D.A. et al. (2004) Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. Prostate, 61, 215-227.
22. Singh,R.P. et al. (2004) Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin. Cancer Res., 10, 8641-8647.
23. Gu,M. et al. (2005) Silibinin inhibits ultraviolet B radiation-induced mitogenic and survival signaling, and associated biological responses in SKH-1 mouse skin. Carcinogenesis, 26, 1404-1413.
24. Li,T.H. et al. (2007) A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. Nucleic Acids Res., 35, 2767-2776.
25. Aggarwal,B.B. et al. (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol., 71, 1397-1421.
26. Deep, G. et al. (2010) Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev., 29, 447-463.
27. Gullett,N.P. et al. (2010) Cancer prevention with natural compounds. Semin. Oncol., 37, 258-281.
28. Harvey,A.L. (2008) Natural products in drug discovery. Drug Discov. Today, 13, 894-901.
29. Singh,R.P. et al. (2004) A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer. Mutat. Res., 555, 21-32.
30. Predel,H.G. et al. (2005) Efficacy of a comfrey root extract ointment in comparison to a diclofenac gel in the treatment of ankle distortions: results of an observer-blind, randomized, multicenter study. Phytomedicine, 12, 707-714.
31. Cheng,H. et al. (2006) Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res., 66, 10613-10620.
32. Eder,I.E. et al. (2002) Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther., 9, 117-125.
33. Solit,D.B. et al. (2003) Hsp90 as a therapeutic target in prostate cancer. Semin. Oncol., 30, 709-716.
34. Solit,D.B. et al. (2002) 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res., 8, 986-993.
35. Zegarra-Moro,O.L. et al. (2002) Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res., 62, 1008-1013.
36. Scher,H.I. et al. (2004) Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr. Relat. Cancer, 11, 459-476.
37. Hååg,P. et al. (2005) Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J. Steroid Biochem. Mol. Biol., 96, 251-258.
38. Knudsen,K.E. et al. (1998) Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J. Biol. Chem., 273, 20213-20222.
39. Tong,Q. et al. (2003) Effects of blocking androgen receptor expression with specific hammerhead ribozyme on in vitro growth of prostate cancer cell line. Chin. Med. J., 116, 1515-1518.
40. Agus,D.B. et al. (1999) Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J. Natl. Cancer Inst., 91, 1869-1876.
41. Wang,L.G. et al. (2001) Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line. Cancer Res., 61, 7544-7551.
42. Feldman,B.J. et al. (2001) The development of androgen-independent prostate cancer. Nat. Rev. Cancer, 1, 34-45.
43. Kerr,J.F. et al. (1973) Deletion of cells by apoptosis during castration-induced involution of the rat prostate. Virchows Arch. B. Cell Pathol., 13, 87-102.